Major News/Events :

Future Waves Design Win -- May 2007

Key Development Milestone -- Feb 2007

Toumaz Wins Oracle Award -- Dec 2006


Nanoscience Inc, is a specialist niche investor in emerging technologies with
strong commercial propositions from within the growing nanotechnology sector.

Web Sites of companies in which NAN has an interest :

http://www.toumaz.com/

http://www.f-waves.com/

http://www.appliedsensor.com

http://www.xrt.com.au/

2

3

4

1st of May media article :


http://www.rfdesignline.com/news/showArticle.jhtml?articleID=199202875


RF group Toumaz joins health alliance standards body

By John Walko

LONDON RF chip developer Toumaz Technology Ltd has become a leading player in the Continua Health Alliance, an industry organization promoting interoperability across technology-based health devices and networks.
The group, seen as an important driver for standards and technology collaboration in the area of medical electronic devices such as body monitors, includes companies such as Intel, Philips, Cisco, Medtronic, Motorola and Samsung.

Toumaz (Abingdon, England) has recently tested its integrated Sensium platform in a device aimed at health and lifestyle monitoring. The company says the chip, which taped-out on Infineon's 130-nm RF CMOS process in November 2006 less than 18 months after initial specification, has met all targeted accuracy and performance parameters in initial functional testing.

The platform incorporates an ultra-low power wireless transceiver (including both RF and baseband functionality), reconfigurable sensor interface and digital block with a low power 8051 processor and memory on a single 4 x 4 mm chip.

The company says it has already started participating in standards setting activities in the Alliance.

"Toumaz's vision of proactive, cost-effective personal connected healthcare is shared by the members of the Continua Alliance," said Toumaz Technology Co-Founder and COO, Keith Errey in a statement.

"As the provider of a key enabling technology in the emerging personal telehealth ecosystem, it is obviously vital for Toumaz to take a role in this important organization and support it in its aim - to deliver highly integrated systems that work together to improve the quality of people's lives," Erey added.

It will be interesting to see how AppliedSensor get on now as well, after BMW started using their one of their range.


AppliedSensor Provides Hydrogen Detection Sensors for

First Hydrogen Serial Car in the Premium Segment

Warren, New Jersey March 16, 2007

AppliedSensor today announced that its HSS-440 hydrogen gas detection module will be incorporated in the BMW Hydrogen 7, the world's first hydrogen-drive luxury performance automobile for everyday use. The Hydrogen 7 automobiles are being built by BMW in a limited series and deployed to selected users in the U.S. and other countries.

The BMW Hydrogen 7, which made its world premiere at the Los Angeles Auto Show in December 2006, uses hydrogen combustion technology available through a dual-mode drive system. At the flick of a dashboard-mounted switch, the driver can tap either a 19.5-gallon gasoline tank or the 17.6-pound liquid hydrogen tank, thereby increasing range and reducing emissions to water vapor.

The AppliedSensor HSS-440 module incorporates high-performance sensing based on advancements in Field Effect (FE) technology designed specifically for fuel cell and hydrogen-powered vehicles. The modules are mounted in the car cabin, under the hood and in the trunk area to detect hydrogen gas leaks at levels far below the established lower explosion limit of four percent in-air.

AppliedSensor is the only supplier that can meet BMWs demanding requirements for hydrogen detection in terms of sensitivity, reliability, speed of response, and operational safety, said AppliedSensor CEO Dr. Robert Straubinger. Our development of sensors for hydrogen-powered vehicles demonstrates our commitment to help drivers lower emissions and reduce their dependence on fossil fuels.

The BMW Group (www.bmwgroup.com) is the only manufacturer of automobiles and motorcycles worldwide that concentrates entirely on premium standards and outstanding quality for all its brands and across all relevant segments

AppliedSensor (www.appliedsensor.com) is a leading provider of gas sensor solutions for air quality, safety and control. With a 25-year legacy of research and development, the company brings its expertise in chemical sensor systems to a broad range of industries and applications, from automotive, heating, ventilation and air-conditioning (HVAC), to safety and air quality control. AppliedSensor operates facilities in Sweden, Germany and the United States.

http://www.electronicstalk.com/news/toz/toz113.html

Product category: Sensors and Data Acquisition
News Release from: Toumaz Technology
Edited by the Electronicstalk Editorial Team on 3 May 2007

.................................


.

Some interest today.

250K protected buy at 11p.

L2 all blue and now 2 v 2 @10.75/11.

http://www.investegate.co.uk/Article.aspx?id=20070529070000P742E

Nanoscience Inc 29th May 2007

Toumaz Technology Signs LOI with Healthe To Collaborate on Sensium Solutions for Sports Medicine

Agreement With Leading Health and Wellness Group To Develop Sensium-Based Applications For Elite Athlete Training and Sport Optimisation


Nanoscience Inc, the specialist niche investor in emerging technologies with strong commercial propositions from within the growing nanotechnology sector, is pleased to announce that its wholly owned subsidiary, Toumaz Technology Limited (`Toumaz') has signed a Letter of Intent (`LOI') with health and wellness group Healthe International Pte Ltd to jointly develop solutions for sports medicine and rehabilitation therapy applications.

The agreement marks the start of a collaboration to trial solutions based on Sensium enabled, ultra small, body-worn, wireless monitors and Healthe's database for elite athletes, Healthe Sport. Toumaz's Sensium sensor interface and transceiver platform enables intelligent, ultra-low power wireless monitoring of multiple vital signs - including ECG heart rate, body temperature, respiration and activity level - in real-time, via standard PDAs,
cellphones, laptops and PCs.

Ben Thynne, Managing Director of Healthe International, commented:

"The signing of this LOI is the first step in a very exciting collaboration between our two companies. The potential for Toumaz's Sensium technology in the sports medicine market is immense, and we look forward to exploring opportunities to combine the strengths of our offerings and delivering a new wave of sports monitoring applications fit for the world's top athletes."

Keith Errey, Toumaz Co-Founder and COO, added:

"Healthe is an internationally recognised leader in the field of sports healthcare management, and we are delighted to be announcing the start of our commercial relationship," "We see huge opportunities for a combined Sensium and Healthe Sports solution to have a positive impact in areas such as training, sport optimisation and post-operative fitness, and we look forward to working together to bring these solutions to market."

Interims out today :

http://www.investegate.co.uk/Article.aspx?id=20070926070000PDF34


.

http://www.investegate.co.uk/Article.aspx?id=20071130070000PA221

Nanoscience Inc.

(`Nanoscience' or the `Group')

Strategic Development and Distribution Alliance

Nanoscience is pleased to announce that its wholly owned subsidiary, Toumaz
Technology Limited (`Toumaz'), has entered into a Strategic Development and
Distribution Alliance (the `Alliance') with a leading global medical devices
business (the `Strategic Partner'). Through the Alliance it is intended that
the two parties will develop agreed solutions, incorporating Toumaz's Amx
technology and its Sensium platform, that will be sold into global healthcare
markets with the objective of becoming global leaders in handheld and body worn
wireless diagnostic and monitoring products. It is envisaged that these next
generation monitoring products will be disposable, non invasive and capable of
providing real time critical vital sign information. From the inception of the
Alliance Toumaz will receive funds from its Strategic Partner for further
development work.

Furthermore, the Strategic Partner has committed to provide funding and
resources to assist in gaining any necessary regulatory approvals and will
carry out global manufacturing, product marketing, sales and distribution.

The Directors of Nanoscience estimate, on the basis of existing market data,
that the vital sign monitoring market already exceeds $1.5bn and continues to
grow, whilst the Point of Care diagnostics worldwide market is estimated at
$10bn and growing.

Toumaz will retain all the background intellectual property relating to its AMx
platform and will be entitled to explore further revenue streams for the
technology outside of the field of use being exploited jointly with its
Strategic Partner.

It is anticipated that ongoing success within the program will result in a
growing financial and technical commitment from Toumaz's Strategic Partner and
the Board look forward to reporting on further progress in the first half of
next year.

Nanoscience has provided Toumaz with ongoing research and development funding
and has continued to work closely alongside its management team to provide the
additional commercial and corporate expertise that has resulted in the
establishment of this landmark alliance.

Chris Toumazou, Chairman of Toumaz Technology Limited, commented:

`The establishment of this alliance is a very positive development for Toumaz,
and we now have the opportunity to provide end to end solutions in the
personalized healthcare space. This has been a key strategic goal of the
business that we now believe is deliverable.'

Guy Spelman, Nanoscience's CEO, commented:

`This is the most significant landmark in the seven year history of Toumaz as
the road to commercialisation is now visible and we look forward to reporting
on further progress throughout 2008.'

Glad you're keeping your eye on things after all PP! This is excellent news for the company as it will set them on the road to commercialisation. Also medical devices, especially in diagnostics, is an area that is set to rise (can't just put my hand on a relevant article to post here).

PapalP .... you seem to be following this stock closely on more than one BB ..... any thoughts / rumours on who the `Strategic Partner' is....?

Comments over at AFN of it possibly being "Medtronic".


I suggest reading thos post from AFN, copied below :


"""""""""spekky - 28 Nov'07 - 09:44 - 247 of 268

If your one of those people who only do the occasional bit of research on your chosen share,then this should be the one its a MUST READ.

http://www.raeng.org.uk/events/pdf/Welcome_Trust_transcript.pdf

Pages 25-38 is a transcript of a speech on 29/10/07 at the royal academy of engineering by prof.Chris Toumazou.

AMAZING STUFF (even i can understand it).Look particularly at those companies he mentions."""""""""""

PP... thanks for reply ..... would certainly be interesting if it was ?Medtronic:

"Medtronic is the global leader in medical technology ...... Revenue for the year ended April 27, 2007: $12.3 billion...... New York Stock Exchange ticker: MDT."

From RNS today:

Nanoscience, the specialist niche investor in emerging technologies with strong
commercial propositions from within the growing nanotechnology sector, is
pleased to announce that its wholly owned subsidiary, Toumaz Technology Limited
(`Toumaz') has been granted its core patent surrounding the AMx (Advanced
Mixed Signal) technology in the key jurisdiction of Australia. The new patent,
already granted in the UK and the US, covers the core technology that enables
the Sensium platform to operate using orders of magnitude lower power than
existing semi-conductor solutions, leading to a dramatic reduction in battery
size for portable devices and extended operating times.

Full details at:
RNS re Patent Grant

Every patent helps..... Let's see if NAN will get a mention in the financial press in a couple of weeks time as one of the stock picks for 2008......

Anyone with a theory on what looks like a huge rollover trade?

No theory personally. But someone on another board had the opinion that it was a transfer between institutions via a broker. Perhaps SAAD were involved. If so, an RNS will follow.

http://www.investegate.co.uk/Article.aspx?id=20080124070000P7544

Nanoscience Inc.

(`The Group')

Toumaz Technology Awarded ISO 13485 Medical Device Quality

Management Certification for Sensium Wireless Body

Monitoring Platform

Toumaz's commitment to the highest quality management standard required for
medical device manufacture recognised by independent accrediting body

Nanoscience Inc, the specialist niche investor in emerging technologies with
strong commercial propositions from within the growing nanotechnology sector,
is pleased to announce that its wholly owned subsidiary Toumaz Technology
Limited (`Toumaz') has received ISO 13485:2003 certification for its quality
management system. ISO 13485 is the regulatory standard for the international
medical industry and is closely related to ISO 9000. Toumaz (a leading provider
of ultra-low power wireless infrastructure for body monitoring solutions) was
assessed and certified as meeting the requirements of this strategically
significant standard by independent body SGS, the world's leading verification
and certification body.

ISO 13485 is a regulatory requirement in a number of international markets for
the manufacture of medical devices, and forms the cornerstone for the CE
certification of medical products in the EU. Meeting the ISO quality management
standard is a crucial milestone in the ongoing commercialisation of Sensium,
Toumaz's breakthrough ultra-low power wireless platform for the development of
non-intrusive body monitors for healthcare and lifestyle markets. In November
2007, Toumaz took the top honours in the Electronics category of the
prestigious Innovation in Engineering Awards - given by The Institution of
Engineering and Technology - in recognition of the groundbreaking innovation of
the Sensium as an enabling technology for highly valuable medical applications.

Keith Errey, COO, Toumaz, commented:

"We are delighted that Toumaz has been awarded the important ISO 13485
certification, which demonstrates our absolute commitment to quality throughout
the product cycle including the manufacture of medical devices, and which will
offer significant benefits to our customers."

The unique combination of ultra-low power wireless and signal processing in one
small System-on-Chip (SOC) allows the economies of scale of the semiconductor
industry to be harnessed to provide highly functional, robust, low cost,
disposable and non-intrusive monitors for a wide range of healthcare
applications.

The Sensium sensor interface and transceiver platform enables real-time,
intelligent, ultra-low power wireless monitoring of multiple vital signs - such
as ECG, heart rate, body temperature, respiration and physical activity (via a
3-axis accelerometer) - and is currently being developed in both disposable and
non-disposable body monitoring products.



- Ends -

About Toumaz Technology (www.toumaz.com)

Toumaz Technology Limited is the leading provider of ultra-low power wireless
infrastructure for body monitoring solutions.

Toumaz's ultra low-power smart sensor interface and transceiver platform - the
Sensium - enables non-intrusive, real-time wireless monitoring of multiple
vital signs for a wide range of healthcare and lifestyle management
applications. Based on Toumaz's patented ultra-low power Advanced Mixed Signal
(AMx) technology, the Sensium provides the enabling technology to connect the
mobile individual to healthcare providers - simply, affordably and
unobtrusively.

For healthcare professionals, this transforms the possibilities for pro-active
monitoring and improved quality of care. For patients, it delivers new
opportunities for lifestyle-compatible, personalised healthcare, as well as
better therapeutic outcomes.

Nanoscience Inc
11 April 2008

Nanoscience Inc.
('Nanoscience' or the 'Group')

Toumaz Technology As Part of Consortium That Wins 7.1 million European
Community Grant

Nanoscience, the specialist niche investor in emerging technologies with strong
commercial propositions for the healthcare and electronic sectors, is pleased to announce that its wholly-owned subsidiary Toumaz Technology Limited ('Toumaz'), is part of a major collaborative research project that has been awarded a 7.1 million grant to fund the development of a portable blood glucose predictor system for diabetes patients.

The Personal Glucose Predictive Diabetes Advisor ('DIAdvisorTM') system is a
unique personalised blood glucose prediction tool that allows patients at any
time to actively and accurately predict their short-term blood glucose outlook
by the analysis of data retrieved from glucose measurements, insulin delivery
data and specific patient parameters, which will be captured by non-intrusive
body-worn wireless monitors based on Toumaz's breakthrough SensiumTM platform.

The grant award, made under the Seventh Framework Programme (FP7) of the
European Community, will fund the four-year research and development project
into the DIAdvisorTM system. The large-scale project is being coordinated by
Novo Nordisk A/S, a world leader in diabetes care, and will be delivered by a
consortium of 13 medical, industrial and academic partners, including the
European Division of the International Diabetes Federation.

Toumaz's role in the project will be to implement the DIAdvisorTM hardware and
software platform, leverage the SensiumTM intelligent data acquisition platform
and networking infrastructure to enable multiple vital signs measurements from
non-intrusive body-worn monitors to be taken and merged with manually entered '
spot' measurements (such as food intake), providing the key data for the
creation of physiological mathematical modeling, control and prediction
algorithms. The resulting analysis and prediction information will then be able
to be wirelessly transmitted to a healthcare provider advisory service, with
recommended action and treatment advice presented to the patient via a handheld
mobile device such as a Personal Digital Assistant (PDA).

First stage data gathering and clinical trials are planned to start in August
2008, with initial data expected by the end of the year.

Dr Alison Burdett, Director of Technology for Toumaz commented:

'With DIAdvisorTM, we will be putting a sophisticated treatment advisor in the
hands of patients for the first time, empowering them in their own healthcare
management and significantly reducing the likelihood of serious complications
and recurrent hospitalisation due to poor glucose control. For healthcare
providers, DIAdvisorTM will have a significant positive impact on cost reduction for the treatment of diabetes.'

Guy Spelman CEO of Nanoscience commented:

'This is further good news from our investment in Toumaz and its development of
the SensiumTM platform. Recognition of the growing importance of the SensiumTM
platform in more sectors in the field of medicine provides further evidence of
its versatility and increasing acceptance across global leaders and government
bodies.'


- Ends -